Impact of Nuedexta on Bulbar Physiology and Function in ALS
Status:
Active, not recruiting
Trial end date:
2021-12-30
Target enrollment:
Participant gender:
Summary
Nuedexta is FDA approved for the treatment of pseudobulbar affect in ALS patients and
anecdotal reports of improvements in speech, salivation or swallowing have been reported.
However, no prospective study has been conducted to comprehensively examine and determine the
physiologic impact of Nuedexta on both speech and swallowing physiology in a large group of
ALS individuals. These data are needed in order to provide evidence-based guidance to the
management of bulbar dysfunction in ALS.